This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Halushka, M. K. Articles by Halushka, P. V. Search for Related Content PubMed PubMed Citation Articles by Halushka, M. K. Articles by Halushka, P. V. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB ACETYLSALICYLIC ACID

(Circulation. 2002;105:1620.)
© 2002 American Heart Association, Inc.

Editorials

Why Are Some Individuals Resistant to the Cardioprotective Effects of Aspirin?

Could It Be Thromboxane A₂?

Marc K. Halushka, MD PhD; Perry V. Halushka, PhD MD

From the Department of Pathology, Johns Hopkins University School of Medicine (M.K.H.), Baltimore, Md, and the Departments of Pharmacology and Medicine, Medical University of South Carolina (P.V.H.), Charleston, SC.

Correspondence to Perry V. Halushka, PhD, MD, Medical University of South Carolina, 173 Ashley Ave, Room 102 CSB, Charleston, SC 29425. E-mail halushpv@musc.edu

Key Words: Editorials • aspirin • thromboxane

It has been slightly more than 100 years since the synthesis, development, and commercialization of acetylsalicylic acid, the most widely consumed drug in the world. It is estimated that 35 000 kg are consumed daily in the United States and 6000 kg in the UK.¹ Who would have ever thought that this widely consumed drug would achieve significant uses other than as an analgesic, antipyretic, and anti-inflammatory. The first report of a possible antithrombotic effect of aspirin appeared in 1953 in the Mississippi Valley Medical Journal.² Dr Craven noticed that the patients who took Aspergum had a tendency to bleed more easily. He concluded that aspirin must be thinning the blood and because thrombosis of the coronary arteries led to myocardial infarction, if his patients took aspirin, they might be less prone to experiencing a myocardial infarction.

See p 1650

These prescient observations were succeeded by the discovery by numerous investigators that aspirin could significantly decrease platelet function. In 1971, the mechanism by which aspirin inhibited platelet function began to unfold when Smith and Willis³ demonstrated that aspirin inhibited platelet prostaglandin synthesis. It was subsequently shown that aspirin irreversibly acetylated serine-529 close to the active site of the fatty acid cyclooxygenase (COX).⁴ In the case of the anucleate platelet, the enzyme is rendered inactive for its lifetime.

Samuelsson and co-workers⁵ demonstrated that thromboxane A₂ along with prostaglandin H₂ were the arachidonic acid metabolites responsible for activation of the platelet. Thromboxane A₂ is also a very effective vasoconstrictor and mitogenic . . . [Full Text of this Article]

This article has been cited by other articles:

				I. Avalos, C. P. Chung, A. Oeser, G. L. Milne, H. Borntrager, J. D. Morrow, P. Raggi, J. Solus, and C. M. Stein Aspirin therapy and thromboxane biosynthesis in systemic lupus erythematosus Lupus, December 1, 2007; 16(12): 981 - 986. [Abstract] [PDF]

				A. L. Frelinger III, M. I. Furman, M. D. Linden, Y. Li, M. L. Fox, M. R. Barnard, and A. D. Michelson Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-Dependent but Cyclooxygenase-1- and Cyclooxygenase-2-Independent Pathway: A 700-Patient Study of Aspirin Resistance Circulation, June 27, 2006; 113(25): 2888 - 2896. [Abstract] [Full Text] [PDF]

				M. Hermann, H. Krum, and F. Ruschitzka To the Heart of the Matter: Coxibs, Smoking, and Cardiovascular Risk Circulation, August 16, 2005; 112(7): 941 - 945. [Full Text] [PDF]

				B. F. McAdam, D. Byrne, J. D. Morrow, and J. A. Oates Contribution of Cyclooxygenase-2 to Elevated Biosynthesis of Thromboxane A2 and Prostacyclin in Cigarette Smokers Circulation, August 16, 2005; 112(7): 1024 - 1029. [Abstract] [Full Text] [PDF]

				R. Gonzalez-Conejero, J. Rivera, J. Corral, C. Acuna, J. A. Guerrero, and V. Vicente Biological Assessment of Aspirin Efficacy on Healthy Individuals: Heterogeneous Response or Aspirin Failure? Stroke, February 1, 2005; 36(2): 276 - 280. [Abstract] [Full Text] [PDF]

				M. Cattaneo Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance Arterioscler. Thromb. Vasc. Biol., November 1, 2004; 24(11): 1980 - 1987. [Abstract] [Full Text] [PDF]

				P. Gresele and R. Migliacci Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? Eur. Heart J., October 2, 2004; 25(20): 1769 - 1771. [Full Text] [PDF]

				F. M. Pulcinelli, P. Pignatelli, A. Celestini, S. Riondino, P. P. Gazzaniga, and F. Violi Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients J. Am. Coll. Cardiol., March 17, 2004; 43(6): 979 - 984. [Abstract] [Full Text] [PDF]

				M. Sacco, F. Pellegrini, M. C. Roncaglioni, F. Avanzini, G. Tognoni, and A. Nicolucci Primary Prevention of Cardiovascular Events With Low-Dose Aspirin and Vitamin E in Type 2 Diabetic Patients: Results of the Primary Prevention Project (PPP) trial Diabetes Care, December 1, 2003; 26(12): 3264 - 3272. [Abstract] [Full Text] [PDF]

				E. Tuleja, F. Mejza, A. Cmiel, and A. Szczeklik Effects of Cyclooxygenases Inhibitors on Vasoactive Prostanoids and Thrombin Generation at the Site of Microvascular Injury in Healthy Men Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1111 - 1115. [Abstract] [Full Text] [PDF]